Which people with metastatic prostate cancer benefit most from upfront docetaxel?

New results from our first STOPCAP M1 individual participant data meta-analysis have been published in The Lancet Oncology and show that adding docetaxel to hormone therapy is more beneficial for some people with advanced prostate cancer than others.